The big shrink
GLP-1 weight loss drugs are triggering sweeping economic spillovers beyond healthcare, with Goldman Sachs estimating a 0.4% GDP boost from improved productivity while forcing food and apparel industries to rapidly adapt to shrinking consumer waistlines and changing purchasing patterns.